We are incredibly grateful to the community of researchers, clinicians, donors and patients who are supporting efforts to discover a cure for fibrolamellar. In spite of the issues caused by the Covid pandemic, highlights of 2021 include:
- The launch of two clinical trials for FLC
- The successful (virtual) gathering of over 70 scientists for the 4th biennial international Fibrolamellar Research Summit
- Increased patient participation in the biobanking and data collection efforts critical to support research.
As we celebrate the progress the community has made in 2021, we also honor the memory of those we have lost by expanding our support of the collaborative research necessary to bring better treatments to fibrolamellar patients. To date, FCF’s cumulative funding of FLC-specific research exceeds $9 million across 20 institutions.
In the video below, Marna Davis (Chair of the Fibrolamellar Cancer Foundation) and several fibrolamellar patients express thanks to those who have made that research progress possible.
From all of us at the Fibrolamellar Cancer Foundation, thank you for helping to improve the lives of those affected by FLC and best wishes for the new year!